Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Assets (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Assets for 6 consecutive years, with $228.8 million as the latest value for Q4 2025.

  • Quarterly Assets fell 38.35% to $228.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $228.8 million through Dec 2025, down 38.35% year-over-year, with the annual reading at $228.8 million for FY2025, 38.35% down from the prior year.
  • Assets for Q4 2025 was $228.8 million at TScan Therapeutics, down from $262.2 million in the prior quarter.
  • The five-year high for Assets was $374.9 million in Q2 2024, with the low at $130.0 million in Q2 2021.
  • Average Assets over 5 years is $248.4 million, with a median of $240.8 million recorded in 2024.
  • The sharpest move saw Assets soared 278.2% in 2021, then plummeted 38.35% in 2025.
  • Over 5 years, Assets stood at $188.1 million in 2021, then rose by 5.84% to $199.1 million in 2022, then skyrocketed by 36.7% to $272.1 million in 2023, then soared by 36.37% to $371.1 million in 2024, then tumbled by 38.35% to $228.8 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $228.8 million, $262.2 million, and $298.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.